

ACADEMIA
OPHTHALMOLOGICA
BELGICA

Viermaandelijks tijdschrift
Périodique quadri mensuel

INFO

AMICO

2026 SATURDAY
28 MARCH



Kantoor van uitgifte – 1040 Brussels

MAART
2026
MARS

N° 141



INFO

INFO Nr 141

MAART - MARS 2026

Viermaandelijks informatieblad
Périodique quadri mensuel

Verantwoordelijke uitgever /
Editeurs responsable
AOB Office
Nijverheidsstraat 24
Rue de l'Industrie
1040 Brussels

info@ophthalmologia.be
www.ophthalmologia.be

INHOUDSTAFEL / SOMMAIRE

EDITORIAL

- 5 Editorial AOB President

IN MEMORIAM

- 7 Dr Pierre Heintz - Mrs Colette Heintz-De Bree

INGEZONDEN BIJDRAGE / COMMUNICATIONS

- 8-11 Membership SOOS/UPBMO-GBS/ABSYS
12 Art Exhibition Baron C.E. Schelfhout

MEETINGS & CONGRESSES

- 13 Enseignement post-universitaire d'ophtalmologie 2026-2027
14 SBO Réunion de Printemps 2026

- 15-18 ManaMa Courses
19-31 AMICO 2026
32-33 PedLowNoc Spring Meeting 2026
34-35 51st ECLSO Congress
37-40 BSCRS Spring Meeting 2026
41 BRS Fab Spring Meeting 2026
42 AMS 2026

CALENDAR – ZOEKERTJES / PETITES ANNONCES

- 43 Calendar Congresses - Meetings
46 Zoekertjes / Petites annonces



SPECIAL FEATURE AMICO 2026

- 20-21 President's Message
22 Programme Overview
23 AMICO - Our Sponsors

AMICO SCIENTIFIC SESSIONS

- 24 BRS
25 PedLowNoc
26 BSA
27 BSOPRS
28 OBAO
29 BSCRS
30 SBO
31 Industry Sessions

FEATURED MEETING

2026

VERSCIJNINGSDATA DATES DE PUBLICATION

INFO N° 142
29-05-2026

INFO N° 143
02-11-2026

SPONSORED ADVERT

Teva Ranivisio® 36

The background features a light blue field filled with a dense, intricate pattern of thin, wavy, interconnected lines that resemble a network or a complex web. A white, angular shape, resembling a folded piece of paper or a stylized 'L' shape, is positioned in the lower-left quadrant, partially overlapping the blue background and the text.

INFO

EDITORIAL



Dear Colleagues,

As we begin 2026, we do so with a sense of determination and cautious optimism - a mindset we are proud to share with you as we present the very first edition of our INFO magazine for the year.

Looking back, 2025 was marked by a particularly successful edition of the Ophthalmologica Belgica Congress. The quality of the scientific program, the lively discussions, and the engagement of both young and senior colleagues demonstrated once again how vibrant and collaborative Belgian ophthalmology truly is. My sincere thanks go to all contributors, speakers, organizers, and industry partners who made this possible.

However, we move forward against a backdrop of broader political and economic uncertainty. Many of us are closely following the forthcoming federal healthcare reforms, which may significantly impact hospital financing, physician remuneration, and the general organization of care. While uncertainty naturally raises concern, it also calls for clarity, unity, and thoughtful engagement from our professional community.

The year ahead offers two important opportunities to connect. I warmly invite you to AMICO, Annual Meeting in Clinical Ophthalmology, held on 28 March 2026. This virtual format continues to provide accessible, high-quality clinical updates for colleagues across the country.

Later, we will gather again for the Ophthalmologica Belgica Congress 2026, which will take place from 25 to 27 November at the well-known Square Brussels. Preparations are already underway to deliver a forward-looking program that addresses the evolving needs of our field.

In these uncertain times, Academia Ophthalmologica Belgica remains committed to fostering scientific exchange, supporting young ophthalmologists, and strengthening collaboration across all subspecialties.

I thank you for your continued engagement and wish you a productive, inspiring, and healthy year 2026.

With kind regards,

Paulina Bartoszek
AOB President



IN MEMORIAM



Quand on n'a que l'amour
A s'offrir en partage
Au jour du grand voyage
Qu'est notre grand amour

Met diep verdriet, maar dankbaar voor het leven dat zij mochten leiden,
nemen we afscheid van

dokter

Pierre Heintz

oogarts

echtgenoot van dokter Colette Heintz-De Bree

geboren in Gent op 19 oktober 1937 en
overleden in Brugge op 26 oktober 2025.

en van

dokter

Colette Heintz-De Bree

oogarts

weduwe van dokter Pierre Heintz

geboren in Brugge op 11 maart 1938 en
overleden in Brugge op 5 november 2025

Bernard en Catheline Heintz-Verdegem
Emmanuel en Catharina, Victoria
Alexander en Nathalie
Nicolas en Adeline
Frédéric en Ann Heintz-Van Damme
Margaux en Edouard
Thibault en Hanne
Bernard en Geneviève Beyne-Heintz
Sébastien en Helena
Arnaud en Tanya

hun kinderen, kleinkinderen en achterkleindochter

Het afscheid heeft plaatsgevonden in familiekring.
Hun asurnen werden begraven in de familiekerlder op de begraafplaats Brugge Centraal.

Gelieve dit bericht als kennisgeving te aanvaarden.

Package 2026

SOOS - UPBMO/GBS - ABSYM

Depuis plusieurs années, nous vous offrons une cotisation unique aux différentes organisations qui s'engagent pour notre défense professionnelle.

La mission commune du Syndicat Ophtalmologique (SOOS) et de l'Union Professionnelle Belge des Médecins Ophtalmologistes (UPBMO) est de défendre notre profession et de négocier avec l'INAMI et avec les autorités compétentes. Ils maintiennent également des contacts étroits avec toutes les ophtalmologistes.

Le SOOS fournit un bulletin mensuel avec les dernières nouvelles et des conseils pratiques, les courriels reçoivent réponse et il y a une réunion mensuelle ouverte à tous où on discute des questions professionnelles. Sur le nouveau site www.soos.be, vous trouverez les rapports des réunions précédentes et les tarifs actuels INAMI.

L'Union Professionnelle Belge des Médecins Ophtalmologistes (UPBMO) fait partie du Groupement Belge des Spécialistes ou GBS . Ils ont des avocats qui peuvent nous – et vous- aider.

- Ne signez pas de contrats avec des institutions sans consulter l'UPBMO ou le GBS !

- Ne permettez pas de contrôle de l'INAMI sans d'abord en informer le GBS.

- Envoyez les lettres d'avocats ou de direction d'institution hospitalière à l'UPBMO et profitez d'une assistance juridique gratuite.

L'Absym, l'association Belge des Syndicats Médicaux défend depuis de nombreuses années les intérêts légitimes des médecins. Etant le plus grand syndicat médical en Belgique, il a la réputation d'être un négociateur dur et tactiquement avisé qui pèse sur les décisions du monde politique et de l'INAMI.

C'est pour cela que le SOOS, l'UPBMO/GBS et l'Absym unissent – dans votre intérêt- leur force, leurs connaissances et leur expertise à tous les niveaux en vous proposant une cotisation unique pour l'ensemble de ces organisations.

Le grand avantage est que vous n'avez qu'à payer un seul montant pour l'ensemble.

Vous pouvez payer votre cotisation 2026 comme suit :

<https://www.soos.be/devenir-membre/?lang=fr>

Après avoir choisi le montant de votre cotisation, vous pouvez remplir vos coordonnées et payer en ligne avec une carte de crédit (comme VISA) ou avec PAYPAL.

Via Paypal, vous pouvez effectuer la transaction via votre (vos) compte (s) bancaire (s) lié (s).

Il n'est pas possible de scinder la cotisation et de ne payer que pour une partie du package. Les tarifs restent inchangés malgré la crise.

Candidat Spécialiste	€ 0
1 année de reconnaissance	€ 175
2,3 et 4 années de reconnaissance	€ 405
Reconnaissance cinq ans, et plus	€ 660
éméritus/ pensionné	€ 95
médecins de + de 65 ans avec pratique	€ 390

Nous vous demandons de payer votre cotisation avant le 31/12/25.

Votre nom sur la liste est très important, tout le monde compte! Essayez autant que possible de convaincre les collègues qui hésitent à payer le package et n'oubliez pas de faire votre contribution. Afin que plus tard personne ne vous puisse vous reprocher que c'est votre oubli ou manque de collégialité qui fait la différence! Nous ferons de notre mieux pour défendre vos intérêts car c'est votre contribution qui légitime nos actions.

Package 2026

SOOS - UPBMO/GBS - ABSYM

Depuis plusieurs années, nous vous offrons une cotisation unique aux différentes organisations qui s'engagent pour notre défense professionnelle.

La mission commune du Syndicat Ophtalmologique (SOOS) et de l'Union Professionnelle Belge des Médecins Ophtalmologistes (UPBMO) est de défendre notre profession et de négocier avec l'INAMI et avec les autorités compétentes. Ils maintiennent également des contacts étroits avec toutes les ophtalmologistes.

Le SOOS fournit un bulletin mensuel avec les dernières nouvelles et des conseils pratiques, les courriels reçoivent réponse et il y a une réunion mensuelle ouverte à tous où on discute des questions professionnelles. Sur le nouveau site www.soos.be, vous trouverez les rapports des réunions précédentes et les tarifs actuels INAMI.

L'Union Professionnelle Belge des Médecins Ophtalmologistes (UPBMO) fait partie du Groupement Belge des Spécialistes ou GBS . Ils ont des avocats qui peuvent nous – et vous- aider.

- Ne signez pas de contrats avec des institutions sans consulter l'UPBMO ou le GBS !

- Ne permettez pas de contrôle de l'INAMI sans d'abord en informer le GBS.

- Envoyez les lettres d'avocats ou de direction d'institution hospitalière à l'UPBMO et profitez d'une assistance juridique gratuite.

L'Absym, l'association Belge des Syndicats Médicaux défend depuis de nombreuses années les intérêts légitimes des médecins. Etant le plus grand syndicat médical en Belgique, il a la réputation d'être un négociateur dur et tactiquement avisé qui pèse sur les décisions du monde politique et de l'INAMI.

C'est pour cela que le SOOS, l'UPBMO/GBS et l'Absym unissent – dans votre intérêt- leur force, leurs connaissances et leur expertise à tous les niveaux en vous proposant une cotisation unique pour l'ensemble de ces organisations.

Le grand avantage est que vous n'avez qu'à payer un seul montant pour l'ensemble.

U kan op volgende manier uw lidgeld 2026 betalen:

<https://www.soos.be/lid-worden/?lang=nl>

Na uw lidmaatschapsbijdrage gekozen te hebben, kan u uw gegevens invullen en online betalen met een kredietkaart (zoals VISA) of met PAYPAL of Payconiq. Via Paypal kan u de transactie doorvoeren via uw gekoppelde bankrekening(en).

Het is niet mogelijk het lidgeld te splitsen en maar voor een gedeelte van het pakket te betalen. Deze tarieven blijven onveranderd.

In opleiding	€ 0
1 jaar erkend	€ 175
2,3 en 4 jaar erkend	€ 405
5 jaar erkend en meer	€ 660
Na stopzetting van de beroepsactiviteit	€ 95
Arts +65j met praktijk	€ 390


We vragen uw lidgeld te betalen voor 31/12/25.

Ook uw naam op de lijst is belangrijk, iedereen telt! Probeer zoveel mogelijk twijfelende collega's te overtuigen de package te betalen en vergeet zelf uw bijdrage niet te leveren. Zie dat niemand U later het verwijt kan maken dat het misschien juist uw vergetelheid of gebrek aan collegialiteit is geweest dat het verschil heeft gemaakt! Wij zullen ons uiterste best doen uw belangen te verdedigen want het is uw lidmaatschap dat ons legitimeert dit te doen.

"JARDINS OUVERTS de BELGIQUE"
"NEDERLANDSE TUINENSTICHTING"



Owners HUGUES & CAROL DE WAELE



CHARLES EMMANUEL SCHELFHOUT

SATURDAY 23 & SUNDAY 24 MAY 2026
(10:00-17:00)

"DE ZEEUW"
JARDIN OUVERT
OPEN GARDEN

KILLEDIJK 10 - RETRANCHEMENT (NL)
(close to Knokke-le-Zoute)

Hidden behind the 17th-century fortifications of the Retranchement are two century-old white houses set in the middle of a romantic garden. Several rooms are connected to each other, here by passageways, there by an allée with beautiful vistas leading visitors from one discovery to the next. Numerous hedges and mixed borders composed of an elegant, refined mix of perennials and old roses. The garden and the countryside landscape form a beautiful ensemble.

Baron Charles Emmanuel Schelfhout, student of Jean Glibert at the CAD in Brussels, was a constructivist who favoured black and white. He exhibited alongside Paul Marat, Roger Raveel and Gilbert de Cock. He began drawing seascapes when his eyesight prevented him from sailing and exhibited in numerous galleries and at the National Maritime Museum in Toulon (France). He created Art & Low Vision and its competition for the visually impaired and was knighted for his work as a blind artist.

ENSEIGNEMENT POST-UNIVERSITAIRE D'OPHTALMOLOGIE 2025-2026

Conférences organisées par le Service d'Ophthalmologie de l'Université de Liège

Début des exposes: 20 heures

Mardi 24 mars 2026

**Défis diagnostiques et thérapeutiques
des glaucomes secondaires**

Pr. N. Collignon (CHU Liège)

Dr. P. Lesoinne (CHU Liège)

Mardi 19 mai 2026

**Kératite neurotrophique:
un défi thérapeutique entre cicatrisation et innovation**

Dr. A. Radermecker (CHU Liège)

Mardi 23 juin 2026

**Avancées en rétine médicale:
tout savoir sur le laser à navigation guidée**

Dr. V. Maréchal (CHU Liège)

Dr. F. Amoroso (Créteil)



Lieu: Château de Colonster - Allée des Erables - 4000 Liège

Accès au Château de Colonster

Venant de BXL ou de Namur, prendre la E25 direction Luxembourg, sortie 40 (Embourg), l'entrée du château se situe sur la première route à droite dans la montée vers le Sart-Tilman.



ET SI ON JOUAIT...

7 MARS 2026

CHÂTEAU DE LA VECQUEE

AVENUE DE LA VECQUEE 21, 5000 NAMUR

09:00 Accueil. Dr X. Janssens, Président de la SBO

09:15 Quand la neurologie s'invite en ophtalmologie
Dr Z. Duvigneaud (CHU Brugmann)

09:40 Le Scrabble de la rétine : maîtriser les acronymes en rétine médicale
Drs L. Postelmans (CHU Brugmann) & F. Rasquin (CHU Erasme)

10:05 Alerte à la paupière
Dr Ngoc Tran (CHU Erasme)

10:30 Pause-café

11:00 Transparente, sensible et réfractive : qui suis-je ?
Dr N. Ozturk (Cliniques Universitaires Saint-Luc)

11:25 Glaucoma Quizz : un MIGS de questions
Dr M. Dequinze (CHR La Citadelle, Liège)

11:50 Assemblée Générale de la SBO

12:15 Lunch

13:15 Pièces manquantes du puzzle
Dr P. Bartoszek (Cliniques Universitaires Saint-Luc)

13:40 Qui veut sauver la rétine ?
Dr M. Leflot (CHR La Citadelle, Liège)

14:05 Les uvéites : reconnaître, déjouer, agir.
Drs Lia Judice & Dorine Makhoul (CHU Saint-Pierre)

14:25 Grand quiz final

15:00 FIN



Manama

courses

overview program

2026-2027

2026	March 14, 2026	Vitreoretinal diseases	KULeuven
2026	June 13, 2026	Uveitis	ULB HSP
2026	December, 2026	Neuro-Ophta	ULG

www.opthalmologia.be

ManMa

March 14, 2026

**Master after Master course organized by the
Collegium Ophthalmologicum Belgica**

Update in vitreoretinal diseases

Saturday, March 14, 2026 - 09:00 - 16:00

Head of Department: Prof. Dr. Ingele Casteels

Organizers: Prof. Dr. Peter Stalmans, Dr. Joachim Van Calster, Dr. Ivo De Clerck

Venue:

Onderwijs & Navorming (ON) Gasthuisberg

Auditorium Ga0

Herestraat 49

3000 Leuven

Programme:

See page 2

Parking:

Parking Onderwijs & Navorsing A.

Accesscode: 63952# (include hashtag).

Parking marked on the attached map - see page 3

--- REGISTRATION IS REQUIRED ! ---

Registration:

Visit the website

www.ophtalmologia.be

login and go to

“My Payments”

Select **“ManMa 2026/2”**

>> *Registration is free (but required) for Residents*

Accreditation:

Accreditation is requested.

>> *To receive certificate of attendance / accreditation you need to have registered for the event AND have scanned QR code onsite - Thank you!*

Attendance tracking:

A poster with a QR code will be available on-site for registering your attendance to the course. To ensure proper tracking, the QR code must be scanned twice. At the beginning and the end of the programme.

This process helps us maintain accurate attendance records.

Update in vitreoretinal diseases

Session 1: Diagnosis / imaging in vitreoretinal pathology

- 09:00 - 09:20 Disease classification of the vitreomacular interface.
Ivo De Clerck (UZLeuven)
- 09:20 - 09:40 Artificial intelligence in OCT: Pathfinder.
Jennifer Blackmore (Norwich, UK)
- 09:40 - 10:00 Standardized echography in VR diseases.
Luc Van Os (UZA)
- 10:00 - 10:15 *Coffee break*

Session 2: Vitreoretinal surgery: part 1

- 10:15 - 10:40 New technologies in VR surgery.
Peter Stalmans (UZLeuven)
- 10:40 - 11:00 Treatment of post-surgical macular edema.
Deborah Lipski (ULB)
- 11:00 - 11:20 High myopia, a surgical approach.
Peter Stalmans (UZLeuven)
- 11:20 - 11:40 Vitreoretinal surgery in uveitis.
Joachim Van Calster (UZLeuven)
- 11:40 - 12:00 Surgical options for large macular holes.
Carl Claes (ZAS Augustinus, Antwerpen)
- 12:00 - 13:00 *Lunch break*

Session 3: Vitreoretinal surgery: part 2

- 13:00 - 13:40 Gene therapy: what's on the horizon & surgical technique?
Fanny Nerinckx (UGent)
- 13:40 - 14:00 Vitreoretinal surgery in diabetic retinopathy.
Adrienne Coche (UCL)
- 14:00 - 14:20 Management of complicated cataract surgery.
Fabrice Korczewski (Citadelle, Liège)
- 14:20 - 14:40 Management of Vitreous Cortical Remnants (VCR).
Marc Veckeneer (ZNA)
- 14:40 - 15:00 *Coffee break*

Session 4: Decision making / practical tips & tricks

- 15:00 - 15:15 Decision making in diabetic retinopathy.
Giuseppe Fasolino (VUB)
- 15:15 - 15:30 Exogenous endophthalmitis: a practical approach.
Peter Stalmans (UZLeuven)
- 15:30 - 15:45 Pneumatic vitreolysis for vitreomacular traction.
Ivo De Clerck (UZLeuven)
- 15:45 - 16:00 Differential diagnosis of retinal detachment.
Jean-Marie Rakic (CHU- University of Liège)

16:00 End

ANNUAL MEETING
AMICO
2026 Clinical
Ophthalmology



.....
AOB members only
.....

JOINT MEETING:

- BRS
- BSA
- BSCRS
- BSOPRS
- SBO
- OBAO
- PEDLOWNOC

**SATURDAY
MARCH 28
2026**

**VIRTUAL
CONGRESS**



www.ophtalmologia.be

ANNUAL MEETING

AMICO

2026 Clinical Ophthalmology

Accreditation
Requested

★★★★★

Geachte collega,

Met veel genoegen en oprechte trots nodigen wij u uit voor **AMICO 2026**, de *Annual Meeting in Clinical Ophthalmology*.

Dit virtueel congres brengt de wetenschap rechtstreeks naar u toe. Vanuit het comfort van uw eigen omgeving geniet u van een sterk programma, samengesteld door vooraanstaande wetenschappelijke verenigingen — elk met hun eigen expertise, allemaal met één gemeenschappelijk doel: kennis die u de volgende dag al kunt toepassen in uw klinische praktijk.

Dankzij de ingebouwde chatfunctie is er volop ruimte voor interactie, vragen en collegiaal overleg. Want ook virtueel zijn de beste inzichten het resultaat van echte gesprekken.

Maar daar stopt het niet. Want aan het einde van het jaar wacht **OB 2026** — ons live congres, waar we elkaar eindelijk weer persoonlijk ontmoeten. Een moment van herkenning, inspiratie en verbinding waar we reeds vol verwachting naar uitkijken.

AMICO 2026: verrijk uw kennis vandaag. OB 2026: beleef het samen morgen.

Wij kijken ernaar uit u te verwelkomen.

Werner Dirven
Voorzitter AMICO/OB 2026



www.ophtalmologia.be



Werner Dirven

Cher(e) collègue,

C'est avec grand plaisir et une sincère fierté que nous vous invitons à **AMICO 2026**, l'*Annual Meeting in Clinical Ophthalmology*.

Ce congrès virtuel vous apporte la science directement à vous. Depuis le confort de votre propre environnement, vous profitez d'un programme riche, élaboré par des associations scientifiques de premier plan — chacune avec sa propre expertise, toutes avec un objectif commun : des connaissances que vous pouvez appliquer dès le lendemain dans votre pratique clinique quotidienne.

Grâce à la fonction de chat intégrée, il y a largement de place pour l'interaction, les questions et les échanges entre collègues. Car même en virtuel, les meilleures idées naissent de vraies conversations.

Mais cela ne s'arrête pas là. Car en fin d'année, **OB 2026** vous attend — notre congrès en présentiel, où nous nous retrouverons enfin en personne. Un moment de reconnexion, d'inspiration et de convivialité que nous attendons déjà avec grande impatience.

AMICO 2026 : enrichissez vos connaissances aujourd'hui. OB 2026 : vivez-le ensemble demain. Nous nous réjouissons de vous accueillir.

Werner Dirven
Président AMICO/OB 2026



www.ophthalmologia.be

Programme Overview

ROOM 1	ROOM 2
<p>BRS Advancing Retina Care: Navigating Biosimilars, Visudyne Accessibility and Hydroxychloroquine retinopathy <i>details on page 24</i></p>	<p>PEDLOWNOC Basic Paediatric Eye Exam and treatment. Guidelines for general ophthalmologists and residents <i>details on page 25</i></p>
	<p>BSA When holiday turns double - A Case I have learned from ... from here and there <i>details on page 26</i></p>
<p>INDUSTRY SYMPOSIA 1 <i>details on page 31</i></p>	
<p>INDUSTRY SYMPOSIA 2 <i>details on page 31</i></p>	
<p>BSOPRS The best cases of BSOPRS 2025 <i>details on page 27</i></p>	<p>OBAO Complication management: Turning setbacks into sight <i>details on page 28</i></p>
<p>INDUSTRY SYMPOSIA 3 <i>details on page 31</i></p>	
<p>INDUSTRY SYMPOSIA 4 <i>details on page 31</i></p>	
<p>BSCRS Clinical Decision-Making in Anterior Segment Surgery: Sustainability, Technology, and Surgical Outcomes <i>details on page 29</i></p>	<p>SBO Intelligence artificielle <i>details on page 30</i></p>

AOB members only

AOB Members (who paid membership fee 2026) will receive an email with the url link and login details to access AMICO 2026 one week prior to the congress.

OUR SPONSORS

We like to thank the following companies for their continuous support.

abbvie



Find more details on the ophthalmologia.be website > [Industry @ AMICO](#)



Saturday 28 March 2026

08:30 - 10:00, Room 1

BRS

Belgian Retina Society

Advancing Retina Care: Navigating Biosimilars, Visudyne Accessibility and Hydroxychloroquine retinopathy

Moderators: Julie DE ZAEYTIJD, Werner DIRVEN

08:30 *Welcome by BRS President Dr. Julie De Zaeytijd*

PART 1 - BIOSIMILARS

08:31 **Introduction on biosimilars and results of a survey on acceptance of biosimilars in Belgian ophthalmology**
CAR E

08:50 **Government policy on financing and reimbursement of drugs in medical retina**
HOEKX L

PART 2 - VISUDYNE AVAILABILITY AND BRS ACCESS PROGRAM

09:10 **Update on the current Visudyne situation in Belgium**
DE ZAEYTIJD J

09:20 **Treatment of CSC: When to Use Visudyne - and when not to, in the context of current allocation rules**
DE LA PORTE V, SCHAUWVLIEGHE PP

PART 3 - SCREENING GUIDELINES

09:40 **Update on screening guidelines for hydroxychloroquine retinopathy**
JACOB J

09:59 *Closing Remarks by Dr Werner Dirven*

10:00 *End of Session*

PEDLOWNOC

Pediatric ophthalmology / LowVision / Neuro-Ophthalmology

Basic Paediatric Eye Exam and treatment.
Guidelines for general ophthalmologists and residents

Moderator: Antonella BOSCHI

- 08:30 **Basic Paediatric Eye Exam and Treatment.
Guidelines for general ophthalmologists and residents**
SCHAEKEN N
- 09:10 *Q&A - Closing Remarks*
- 09:15 *End of Session*



Saturday 28 March 2026

09:15 - 10:00, Room 2

BSA

Belgian Strabismological Association

When holiday turns double
A Case I have learned from ... from here and there

Moderator: Sandrine DE TEMMERMAN

09:15 *Welcome*

CASES From here:

09:16 **Non thyroid associated diplopia changes in patient with Graves orbitopathy**
DE NIJS E

09:26 **When myelin gets in the way : a case report**
SERCKX V

CASES From there:

09:36 **A hammock-related ocular trauma in Canada**
HEMPTINNE C, RIZZO L, BROHEZ J

09:46 **A ski trauma**
CASSIMAN C

09:56 *Q&A - Closing remarks*

10:00 *End of Session*

BSOPRS

Belgian Society of Ophthalmic Plastic and Reconstructive Surgery

The best cases of BSOPRS 2025

Moderator: Sofie CAEN

- 10:50 **Sphenoid wing meningioma**
SCHEERS D
- 11:00 **Canthal Retraction**
GOEMAERE J
- 11:10 **Dakin's Solution Case**
HELSEN S
- 11:20 **Orbital Plasmacytoma / epiphora**
CAEN S
- 11:30 Q&A
- 11:35 *End of Session*



Saturday 28 March 2026

10:50 - 11:35, Room 2

OBAO - Organisatie van Belgische Assistenten in Oogheelkunde
Organisation Belge des Assistants en Ophtalmologie

Complication management:
Turning setbacks into sight

Moderators: William GOES

10:50 *Introduction by OBAO President Dr. William Goes*

10:51 **When glasses cannot fix the job**
MATTHYS E

11:06 **Complication management case in vitreoretinal surgery**
NERINCKX F

11:21 **Severe amoebic keratitis associated with uveal effusion requiring surgical treatment**
HADDAD C

11:35 *End of Session*

BSCRS - Belgian Society of Cataract and Refractive Surgeons

Clinical Decision-Making in Anterior Segment Surgery: Sustainability, Technology, and Surgical Outcomes

Moderators: Nashwan AL-SABAI, Thierry DERVEAUX

- 12:18 **When the First Laser Fails:
Femto-Assisted Kerating Implantation in Keratoconus
A Case-Based Video**
AL-SABAI N
- 12:28 **The “Sewing Machine” Suture Technique for Repair of Iris Dialysis**
NI DHUBHGHAILL S
- 12:38 **Management of a Complex Case Using Scleral Fixation of the Carlevalle
Intraocular Lens**
PION B
- 12:48 **How to Perform Cataract Surgery More Sustainably – While Reducing Costs**
LUCAS R
- 13:03 End of Session



Saturday 28 March 2026

12:18 - 13:03, Room 2

SBO - Société Belge d'Ophtalmologie

Intelligence artificielle

Moderators: Laurent LEVECQ

- 12:18 **IA en ophtalmologie: innovations**
QIN V
- 12:38 **IA et maladies rares de l'oeil**
HEMPTINNE C
- 12:58 *Questions & réponses*
- 13:03 *Fin de Session*



Saturday 28 March 2026

10:00 - 10:20 INDUSTRY SESSION 1

Organized by Abbvie

The Abbvie logo, consisting of the word 'abbvie' in a lowercase, sans-serif font.

**OZURDEX® in DME and RVO Management
in Belgium – Impact of new Ozurdex data in DME**

10:20 - 10:40 INDUSTRY SESSION 2

Organized by Chiesi



**From Suspicion to Treatment:
Clinical Management of Leber's Disease**

11:35 - 11:55 INDUSTRY SESSION 3

Organized by CooperVision



**MyDay® contact lenses,
innovation by CooperVision for a lifetime of wear**


11:55 - 12:15 INDUSTRY SESSION 4

Organized by Nordic Pharma



Ocular surface health in the peri-operative setting

Find more details on the ophthalmologia.be website > [Industry @ AMICO](#)



March, 2026

Dear Members of PEDLOW/NOC,

We hope to see you all at our Spring meeting on **Thursday 21th of April 2026** at AZ Sint-Maarten Mechelen.

The meeting will take place at the congress centre in AZ Sint-Maarten in Mechelen (Liersesteenweg 435). Entrance through the main entrance. Parking tickets are available after the meeting. Accreditation has been applied.

To register, please send an email to pedlownoc@gmail.com. The Spring meeting is free for our members and orthoptists, therefore we kindly remind you to renew your membership for PEDLOWNOC in 2026.

Kind regards,
The PEDLOW/NOC board.

A shared Vision

clinical case discussions by PEDLOW/NOC and BOV-ABO

Date: Tuesday, April 21 2026

Place: AZ Sint-Maarten Mechelen

PROGRAMME

- 13:00 **Introduction**
- 13:05 **Do you really know what I see?**
Patrick Hellin / Dr. Delbeke Patricia
- 13:25 **Casus Low vision and explanation of medical filters**
Ann Vandesteene / Ellen Van De Ginste / Dr. Els Vandeweyer
- 13:45 **Unusual early nystagmus**
Cécile Boyer / Dr. Maëlle Coutel
- 14:05 **Medication induced strabismus**
Lien Antoons/ Dr. Pieter Robben
- 14:30 PAUSE
- 15:15 **Nystagmus from exam to treatment plan, case-presentation**
Anna Goffin/ Prof. Dr. Catherine Cassiman
- 15:35 **Casus cataract/uveitis**
Dr. Luc van Os
- 15:55 **Doctor help, the eyes of my child do not move!**
Jérôme Brohez / Dr Balikova Irina / Dr Hemptinne Coralie
- 16:15 Discussion
- 16:45 General Assembly PED/LOW/NOC

Join Us for the 51st ECLSO Congress Advancing Contact Lens and Ocular Surface Science

The European Contact Lens Society of Ophthalmologists (ECLSO) warmly welcomes you to its 51st congress, taking place in Vienna on April 24 and 25, 2026. This meeting offers a unique opportunity for ophthalmologists and other eye care professionals to share expertise and gain new insights into ocular surface pathology and the medical use of contact lenses.

Let me highlight just a few of the scientific sessions. In *“Current State of the Art in Keratoconus,”* the panel will discuss how contact lens and surgical approaches can be tailored to meet each patient’s individual needs. You will also learn directly from the authors of the *“TFOS Dry Eye Workgroup III reports”* who will present the most recent insights into the diagnosis and management of dry eye disease. *“Myopia management”* will be explored in its full breadth, offering an up-to-date overview of the latest strategies and innovations. Additional sessions will address *“Astigmatism correction”* and *“New developments in soft contact lens technology”*. Have a look at the website and check out the full programme at **HOME | ECLSO Congress 2026**.

Why should you register for this meeting? I am convinced that contactology is an integral part of ophthalmological practice. While not every ophthalmologist must be a contact lens expert, all should stay informed about the advances shaping modern eye care. ECLSO 2026 will provide an essential update for every clinician striving to deliver the highest standards of care in cornea and ocular surface disease.

Kind regards,
Carina Koppen
President, ECLSO

ECLSO Grants

A limited number of grants are available to support **young doctors** attending the 2026 Congress. Grants include up to **€200 for travel expenses** and **free registration**, with priority given to applicants **presenting accepted abstracts**.



VIENNA

SESSION TOPICS:

- ASTIGMATISM – FROM A-Z
- A COMPREHENSIVE APPROACH TO KERATOCONUS
- CURRENT STATE-OF-THE-ART IN MYOPIA MANAGEMENT
- HIGHLIGHTS FROM TFOS III
- NEW INSIGHTS IN SOFT CONTACT LENS TECHNOLOGY
- INVITED YOUNG OPHTHALMOLOGISTS INTERESTING CASES
- LOCAL AUSTRIAN SOCIETY SYMPOSIUM – CONTROVERSIES

PLUS:

- RAPID FIRE ON INNOVATION
- FICK-KALT-MÜLLER MEDAL
- FREE PAPERS
- KERSLEY LECTURE

51st ECLSO CONGRESS

*The European Society of
Contact Lenses and Ocular Surface*

APRIL 24-25th 2026
VIENNA

eclso2026.com

JOIN US
in Austria

20%

Discount
for ECLSO
Members



Ranivisio® 10 mg/ml is a biosimilar of Lucentis®* (ranibizumab) and available in Belgium & Luxemburg¹

See what Ranivisio® could do for your patients.²

- ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

* Lucentis® is a licensed product of Novartis Europharm Limited.

Ranivisio® is indicated in adults for the treatment of: neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular oedema (DME); proliferative diabetic retinopathy (PDR); visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); visual impairment due to choroidal neovascularisation (CNV).¹




- ▼ **NAME OF THE MEDICINAL PRODUCT:** Ranivisio 10 mg/ml solution for injection. **QUALITATIVE AND QUANTITATIVE COMPOSITION:** One ml contains 10 mg ranibizumab*. Each vial contains 2.3 mg of ranibizumab in 0.23 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml containing 0.5 mg ranibizumab to adult patients. *Ranibizumab is a humanised monoclonal antibody fragment produced in *Escherichia coli* cells by recombinant DNA technology. For the full list of excipients, see section 6.1. **CLINICAL PARTICULARS: Therapeutic indications:** Ranivisio is indicated in adults for: • The treatment of neovascular (wet) age-related macular degeneration (AMD); • The treatment of visual impairment due to diabetic macular oedema (DME); • The treatment of proliferative diabetic retinopathy (PDR); • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); • The treatment of visual impairment due to choroidal neovascularisation (CNV). **Posology and method of administration:** Ranivisio must be administered by a qualified ophthalmologist experienced in intravitreal injections. **Posology: Adults:** The recommended dose for Ranivisio in adults is 0.5 mg given as a single intravitreal injection. This corresponds to an injection volume of 0.05 ml. The interval between two doses injected into the same eye should be at least four weeks. Treatment in adults is initiated with one injection per month until maximum visual acuity is achieved and/or there are no signs of disease activity i.e. no change in visual acuity and in other signs and symptoms of the disease under continued treatment. In patients with wet AMD, DME, PDR and RVO, initially, three or more consecutive, monthly injections may be needed. Thereafter, monitoring and treatment intervals should be determined by the physician and should be based on disease activity, as assessed by visual acuity and/or anatomical parameters. If, in the physician's opinion, visual and anatomic parameters indicate that the patient is not benefiting from continued treatment, Ranivisio should be discontinued. Monitoring for disease activity may include clinical examination, functional testing or imaging techniques (e.g. optical coherence tomography or fluorescein angiography). If patients are being treated according to a treat-and-extend regimen, once maximum visual acuity is achieved and/or there are no signs of disease activity, the treatment intervals can be extended stepwise until signs of disease activity or visual impairment recur. The treatment interval should be extended by no more than two weeks at a time for wet AMD and may be extended by up to one month at a time for DME. For PDR and RVO, treatment intervals may also be gradually extended, however there are insufficient data to include on the length of these intervals. If disease activity recurs, the treatment interval should be shortened accordingly. The treatment of visual impairment due to CNV should be determined individually per patient based on disease activity. Some patients may only need one injection during the first 12 months; others may need more frequent treatment, including a monthly injection. For CNV secondary to pathologic myopia (PM), many patients may only need one or two injections during the first year (see section 5.1). **Ranibizumab and laser photocoagulation in DME and in macular oedema secondary to BRVO:** There is some experience of ranibizumab administered concomitantly with laser photocoagulation (see section 5.1). When given on the same day, Ranivisio should be administered at least 30 minutes after laser photocoagulation. Ranivisio can be administered in patients who have received previous laser photocoagulation. **Ranibizumab and verteporfin photodynamic therapy in CNV secondary to PM:** There is no experience of concomitant administration of ranibizumab and verteporfin. **Special populations: Hepatic impairment:** Ranibizumab has not been studied in patients with hepatic impairment. However, no special considerations are needed in this population. **Renal impairment:** Dose adjustment is not needed in patients with renal impairment (see section 5.2). **Elderly:** No dose adjustment is required in the elderly. There is limited experience in patients older than 75 years with DME. **Paediatric population:** The safety and efficacy of ranibizumab in children and adolescents below 18 years of age have not been established. Available data in adolescent patients aged 12 to 17 years with visual impairment due to CNV are described in section 5.1 but no recommendation on a posology can be made. **Method of administration:** Single-use vial for intravitreal use only. Since the volume contained in the vial (0.23 ml) is greater than the recommended dose (0.05 ml for adults), a portion of the volume contained in the vial must be discarded prior to administration. Ranivisio should be inspected visually for particulate matter and discoloration prior to administration. The injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent) and the availability of sterile paracentesis (if required). The patient's medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section 4.4). Adequate anaesthesia and a broad-spectrum topical microbicide to disinfect the periorcular skin, eyelid and ocular surface should be administered prior to the injection, in accordance with local practice. **Adults:** In adults the injection needle should be inserted 3.5-4.0 mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe. The injection volume of 0.05 ml is then delivered; a different scleral site should be used if subsequent injections. For instructions on preparation of the medicinal product before administration, see section 6.6. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with active or suspected ocular or periocular infections. Patients with active severe intraocular inflammation. **Undesirable effects: Summary of the safety profile:** The majority of adverse reactions reported following administration of ranibizumab are related to the intravitreal injection procedure. The most frequently reported ocular adverse reactions following injection of ranibizumab are: eye pain, ocular hyperaemia, increased intraocular pressure, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye and eye pruritus. The most frequently reported non-ocular adverse reactions are headache, nasopharyngitis and arthralgia. Less frequently reported, but more serious, adverse reactions include endophthalmitis, blindness, retinal detachment, retinal tear and iatrogenic traumatic cataract (see section 4.4). The adverse reactions experienced following administration of ranibizumab in clinical trials are summarised in the table below. **Tabulated list of adverse reactions²:** The adverse reactions are listed by system organ class and frequency using the following convention: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$), very rare ($< 1/10,000$), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. **Infections and infestations: Very common:** Nasopharyngitis. **Common:** Urinary tract infection². **Blood and lymphatic system disorders: Common:** Anaemia. **Immune system disorders: Common:** Hypersensitivity. **Psychiatric disorders: Common:** Anxiety. **Nervous system disorders: Very common:** Headache. **Eye disorders: Very common:** Vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, eye pain, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, lacrimation increased, blepharitis, dry eye, ocular hyperaemia, eye pruritus. **Common:** Retinal degeneration, retinal disorder, retinal detachment, retinal tear, detachment of the retinal pigment epithelium, retinal pigment epithelium tear, visual acuity reduced, vitreous haemorrhage, vitreous disorder, uveitis, iritis, iridocyclitis, cataract, cataract subcapsular, posterior capsule opacification, punctate keratitis, corneal abrasion, anterior chamber flare, vision blurred, injection site haemorrhage, eye haemorrhage, conjunctivitis, conjunctivitis allergic, eye discharge, photopsia, photophobia, ocular discomfort, eyelid oedema, eyelid pain, conjunctival hyperaemia. **Uncommon:** Blindness, endophthalmitis, hypopyon, hyphaema, keratopathy, iris adhesion, corneal deposits, corneal oedema, corneal striae, injection site pain, injection site irritation, abnormal sensation in eye, eyelid irritation. **Respiratory, thoracic and mediastinal disorders: Common:** Cough. **Gastrointestinal disorders: Common:** Nausea. **Skin and subcutaneous tissue disorders: Common:** Allergic reactions (rash, urticaria, pruritus, erythema). **Musculoskeletal and connective tissue disorders: Very common:** Arthralgia. **Investigations: Very common:** Intraocular pressure increased. ² Adverse reactions were defined as adverse events (in at least 0.5 percentage points of patients) which occurred at a higher rate (at least 2 percentage points) in patients receiving treatment with ranibizumab 0.5 mg than in those receiving control treatment (sham or verteporfin PDT). * observed only in DME population. **Product-class-related adverse reactions:** In the wet AMD phase III studies, the overall frequency of non-ocular haemorrhages, an adverse event potentially related to systemic VEGF (vascular endothelial growth factor) inhibition, was slightly increased in ranibizumab-treated patients. However, there was no consistent pattern among the different haemorrhages. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the ranibizumab clinical trials in patients with AMD, DME, PDR, RVO and CNV and there were no major differences between the groups treated with ranibizumab compared to control. Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions: • in Belgium via the Federaal agentschap voor geneesmiddelen en gezondheidsproducten-Afdeling Vigilantie-Postbus 97, 1000 BRUSSEL Madou-Website: www.eenbijwerkingmelden.be - e-mail: adr@fagg.be; • and in Luxemburg via the Centre Régional de Pharmacovigilance de Nancy of Division de la pharmacie et des médicaments de la Direction de la santé - Website: www.guichet.lu/pharmacovigilance. **MARKETING AUTHORISATION HOLDER:** Midas Pharma GmbH, Rheinstraße 49, D-55218 Ingelheim, Germany. **MARKETING AUTHORISATION NUMBER(S):** EU/1/22/1673/001. **SUPPLY:** Medicinal product subject to medical prescription. **DATE OF REVISION OF THE TEXT:** 11/2025. Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.

References: 1. Ranivisio® (Ranibizumab Midas 10 mg/ml solution for injection) Summary of Product Characteristics. 11/2025. 2. Holz FG et al. Ophthalmology. 2022 doi: 10.1016/j.ophtha.2021.04.031,

Rnvs-BE-00029 - Teva Pharma Belgium
Date of approval FEB 2026

Save the date !



**BSCRS
SPRING
MEETING**

2026

**SATURDAY
MAY 23**

Château de Colonster Liège

Combined Surgeries

Organised by

**BSCRS
BCLSO**



in collaboration with



Organisation of Belgian Residents in Ophthalmology

Dear Colleagues,

It is our pleasure to invite you to the joined **BSCRS OBAO Spring Meeting 2026**. The meeting will take place on Saturday, May 23, 2026, and will be hosted at Château de Colonster - Liège, an elegant historic venue offering a distinctive setting for professional and academic gatherings. Blending classic architecture with modern facilities, it provides a unique environment for networking and knowledge-sharing. The topic of the meeting will be **Combined Surgeries**.

This meeting is designed to provide a high-quality educational program, featuring scientific sessions with expert speakers. A **preliminary program** is available on the next page. The day will conclude with a Farewell Reception.

Alongside the scientific program, there will be an Industry Exhibition Area where leading companies will showcase the latest innovations and technologies in cataract, refractive, and corneal surgery.

We look forward to welcoming you to Liège for an inspiring scientific exchange.

BSCRS & OBAO Organizing Committee

Dr Françoise Van Cauwenberge – BSCRS President

Dr Jean-François Chapelle – Treasurer

Dr François-Xavier Crahay

Prof Jean-Marie Rakic

Dr William Goes – OBAO President

Dr Juliette Levie

Dr Roger Vanschoor



PRELIMINARY PROGRAM

CLICK
HERE



REGISTER NOW

PRELIMINARY SCIENTIFIC PROGRAMME

Combined Surgeries

Organizing Committee:

Dr Françoise Van Cauwenberge – Dr Jean-François Chapelle – Dr François-Xavier Crahay – Prof Jean-Marie Rakic – Dr William Goes – Dr Juliette Levie – Dr Roger Vanschoor

09:00 **Welcome by Dr Françoise Van Cauwenberge - BSCRS President**

09.05 OBAO case presentation (TBD)

09.10 **Keratoconus and cataract**

B. GOLENVAUX

09.25 **Corneal surface and cataract**

S. NI DHUBHGHAILL

09.40 **IOL selection after corneal refractive surgery**

FX. CRAHAY

09.55 **Refractive enhancement after cataract surgery**

JF. CHAPELLE

10.10 **Different approaches for refractive Artisan removal during cataract**

Th. DERVAUX

10.20 *Industry news*

10.30 *Coffee break*

11.00 OBAO case presentation (TBD)

11.05 **Phaco IStent vs Phaco Elios**

V. WALGRAVE

11.20 **Cataract+ MIGS vs cataract + SLT**

S. POURJAVAN

11.35 **Acute glaucoma and cataract**

F. VAN CAUWENBERGE

11.50 **Laser-assisted cataract in complex cases**

N. ALSABAI

12.05 *Industry news*

12:30 BSCRS General assembly

12.55 *Lunch time (+DryLAB for OBAO members)*

continues > ...

PRELIMINARY SCIENTIFIC PROGRAMME

Combined Surgeries

Organizing Committee:

Dr Françoise Van Cauwenberge – Dr Jean-François Chapelle – Dr François-Xavier Crahay –
Prof Jean-Marie Rakic – Dr William Goes – Dr Juliette Levie – Dr Roger Vanschoor

14.00 OBAO Case presentation (TBD)

14.05 **Phaco-vitreotomy with EDOF IOLs in presbyopic myopes**
P. STALMANS

14.20 **Vitreous opacities and cataract**
J.M. RAKIC

14.35 **Cataract surgery in retinal disease**
G. FASOLINO

14.50 **Cataract surgery in trauma**
A. NAJIB

15.05 *Discussion*

15.15 *Tea-time*

15.45 **DEBATE SESSION**

moderated by S. NI DHUBHGHAILL

- **Refractive or diffractive IOL for presbyopia**
F.X. CRAHAY vs Th. DERVAUX
 - **ICL or Laser for low myopia**
N. ALSABAI vs B. GOLENVAUX
 - **Iris or scleral-fixated IOLs in aphakia**
G. SALLET vs B. PION
-

16.30 *End of Scientific Meeting*

We like to thank
OUR SPONSORS
for their continues support

Confirmed sponsors as per March 5th, 2026

GOLD Sponsors

- Alcon
- Hasa Optix
- Ophtalmo Surgical

SILVER Sponsors

- EssilorLuxottica
- Horus Pharma
- ING
- Ursapharm

PRE-CONGRESS SOCIAL EVENT

Kick off the event with the



The scientific meeting will be preceded by the BSCRS Golf Tournament on **Friday, May 22, 2026, from 09:00 to 13:00**, followed by lunch at the exclusive Royal Golf Club of Belgium – Ravenstein (www.rgcb.be).

Fee: €50 (includes lunch)

Golf Registration* Deadline: April 24, 2026

** Only golfers registered for the Spring Meeting can participate in the tournament.*

Limited access - first come, first served.

You can register for the event through your account on the ophthalmologia.be website
> Login > My Payments > Select BSCRS Spring Meeting and follow the instructions.

Congress Sponsors

GOLD Sponsors

- Alcon
- Hasa Optix
- Ophthalmo Surgical

SILVER Sponsors

- EssilorLuxottica
- Horus Pharma
- ING
- Ursapharm

INVITATION FAB MEETING

SATURDAY 06/06/2026



**SAVE
THE DATE**



Dear BRS-member and FAB-enthusiast,

Spring is in the air – and so is the spirit of collaboration and clinical excellence!

We are delighted to invite you to the FAB Spring Meeting 2026, a wonderful opportunity to connect with colleagues, share fascinating cases and celebrate the vibrant community that makes the BRS so special.

Venue:

CHU Liège – Sart Tilman
Avenue de l'Hôpital 1- 4000 Liège

Programme:

08:30 Welcome, breakfast & coffee
09:30 Case presentations
11:00 Coffee break
11:30 Case presentations
13:00 Buffet lunch
14:00 General Assembly BRS

Whether you come to present, to listen or simply to reconnect – your presence makes the difference. Case presentations are warmly welcomed in the language of your choice: NL, FR or ENG.

The meeting is open to all BRS-members and entirely free of charge.

Registration is required for organization purposes.

Ultimate registration deadline 30/05/2026.

You can register using the link below.

>> [CLICK HERE TO REGISTER](#)

We look forward to welcoming you to Liège on June 6th!

The CHU Liège team & The BRS Board

KEYNOTE LECTURES

CLINICAL CASE DISCUSSIONS

AMS.2026

Annual MS Meeting Optic Neuritis Unveiled: Clinical and Imaging Perspectives

Saturday 13TH June 2026 → 09:00 – 12:30

Irish College, Leuven (Belgium)

CHAIRS



Bénédicte Dubois
President of
the BSGMS



Bart Van Wijmeersch
Board Member,
ParadigMS

SPEAKERS

KEYNOTE 01

Clinical aspects of Optic Neuritis



Axel Petzold
University College
London, UK

KEYNOTE 02

Seeing Optic Neuritis Through
Optical Coherence Tomography:
a new biomarker



**Anne-Catherine
Chapelle**
University of Liège, BE

KEYNOTE 03

Optic Neuritis:
A window to the Brain



Jette Frederiksen
University of
Copenhagen, DK

Scientific Programme Highlights

- Welcome & introduction by the Programme Co-Chairs
- Keynote lecture(s) on optic neuritis: clinical & imaging perspectives
- Interactive clinical case discussions
- Practical conclusions & take-home messages

Check the full Programme &

→ REGISTER NOW



CO-HOSTED BY



Groupe Belge d'Etude de la Sclérose en Plaques asbl
Belgische Studiegroep voor Multiple Sclerose vzw



GOLD SPONSOR



BRONZE SPONSORS



WWW.PARADIGMS.FOUNDATION

WWW.BSGMS.ORG



INFO

What's Happening ?

Congresses - meetings - courses - ...

CALENDAR

CONGRESS CALENDAR

07	March	2026	Réunion de Printemps de la SBO Place Château de la Vecquée, Avenue de la Vecquée 21, 5000 Namur ▶ https://www.ophtanet.be Thème: Et si on jouait ensemble ?
24	March	2026	Enseignement post-universitaire d'ophtalmologie Château de Colonster: Allée des Erables, 4000 Liège Défis diagnostiques et thérapeutiques des glaucomes secondaires Pr. N. Collignon (CHU Liège) Dr. P. Lesoinne (CHU Liège) Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège Début des exposés : 20 heures
28	March	2026	AMICO 2026, Annual Meeting in Clinical Ophthalmology Virtual ▶ https://www.ophtalmologia.be/plugins/events/show_schedule.php?ev_id=89 AMICO - Annual Meeting in Clinical Ophthalmology Joint Meeting of the AOB Societies Accredited event
21	April	2026	PedLowNoc / BOV-ABO Springmeeting 2026 AZ Sint-Maarten, Mechelen
24-25	April	2026	ECLSO 2026 Congress Anantara Palais Hotel Conference Centre, Vienna, Austria ▶ https://www.eclso2026.com/ The European Contact Lens Society of Ophthalmologists (ECLSO) welcomes you to the 51st ECLSO Congress A opportunity for ophthalmologists and other eye care experts to share and gain knowledge on ocular surface pathology and medical use of contact lenses.
19	May	2026	Enseignement post-universitaire d'ophtalmologie Château de Colonster: Allée des Erables, 4000 Liège Kératite neurotrophique: un défi thérapeutique entre cicatrisation et innovation Dr. A. Radermecker (CHU Liège) Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège Début des exposés : 20 heures
22-24	May	2026	EuCornea 2026 Alfândega do Porto Congress Center, Porto, Portugal ▶ https://eucornea.org/porto-2026-general-information/ The 17th EuCornea Congress, taking place from Friday 22nd – Sunday 24th May in the Alfândega do Porto Congress Center, Porto, Portugal.
23	May	2026	BSCRS-OBAO Spring Meeting 2026 - Save the date - Château de Colonster - Liège ▶ https://ophtalmologia.be/page.php?edi_id=2261 TOPIC: Combined Surgeries Dr Françoise Van Cauwenberge – Dr Jean-François Chapelle – Dr François-Xavier Crahay – Prof Jean-Marie Rakic – Dr William Goes – Dr Juliette Levie – Dr Roger Vanschoor
06	June	2026	BRS - FAB Spring Meeting 2026 CHU Liège — Sart Tilman Avenue de l'Hôpital 1, 4000 Liège
23	June	2026	Enseignement post-universitaire d'ophtalmologie Château de Colonster: Allée des Erables, 4000 Liège Avancées en rétine médicale: tout savoir sur le laser à navigation guidée Dr. V. Maréchal (CHU Liège) Dr. F. Amoroso (Créteil) Conférences organisées par le Service d'Ophtalmologie de l'Université de Liège Début des exposés : 20 heures

-
- 26-29 June 2026** **WOC 2026 - World Ophthalmology Congress**
Prague, Czech Republic
▶ <https://icoph.org/>
-
- 24-26 September 2026** **51st EPOS Meeting**
Crowne Plaza Hotel - Bucharest, Romania
▶ <https://www.epos2026.org/>
Local Organizer: Daniela Cioplean
-
- 25-27 November 2026** **OB 2026**
SQUARE, Brussels Meeting Center
▶ https://www.opthalmologia.be/page.php?edi_id=2035
-
- 24-26 November 2027** **OB 2027**
SQUARE, Brussels Meeting Center
▶ https://www.opthalmologia.be/page.php?edi_id=2035



INFO

**KLEINE
AANKONDIGINGEN**

PETITES ANNONCES

4/3/2026

Collega oogarts gezocht Antwerpen

Oogarts gezocht in volledig uitgeruste praktijk in centrum Antwerpen.

Oogcentrum Baron Joostensstraat is een nieuwe praktijk met moderne apparatuur en optimale ondersteuning door een team van goed samenwerkende paramedici en secretaresses.

Wij zijn op zoek naar een collega oogarts die ons team met veel enthousiasme wil komen vervoegen. Er is flexibiliteit om het werkrooster en de activiteiten in onderling overleg vorm te geven.

Als je interesse hebt, neem dan zeker contact op met Dr. Sarah Hershko

Tel. 0486401980

E-mail hershkosarah@gmail.com

4/2/2026

Vacature oogarts Oogcentrum Lommel

Oogcentrum Lommel is een extramurale oogartsenpraktijk bestaande uit 2 oogartsen, 2 secretariaatsmedewerkers en een verpleegkundige. Onze moderne praktijk is uitgerust met onder andere een OCT, fluo-angiografie, yag-laser, argonlaser, IOL master en Pentacam. Omwille van de grote vraag naar oogheelkundige zorg in onze regio zijn we op zoek naar een enthousiaste collega om ons team te versterken. We zoeken een collega met brede interesse in oftalmologie, eventueel in combinatie met een specifieke subspecialisatie zoals pediatrie oftalmologie, glaucoom, medische retina, cataract- of ooglidchirurgie.

Voor chirurgische ingrepen is onze praktijk verbonden aan het Noorderhart ziekenhuis te Pelt.

Geïnteresseerde assistenten in opleiding of collega's die graag eens op gesprek komen, gelieve contact op te nemen via mail naar nathalie.vervaet@oogcentrumlommel.be of nathalie.bral@oogcentrumlommel.be

Oogcentrum Lommel - Kapittelhof 16 - 3920 Lommel

www.oogcentrumlommel.be

Tel. 011/100.805

E-mail info@oogcentrumlommel.be

29/1/2026

autorefractor/keratometer en tonometer te koop

Te koop wegens aankoop NIDEK tonoref:

- NIDEK autorefractor/keratometer ARK1A, bouwjaar 2018, perfecte staat, vraagprijs 4.000 euro

- TOPCON PTO tonometer, CT800, bouwjaar 2016, perfecte staat, vraagprijs 3.000 euro

Contactgegevens:

Tel: 0478 47 52 78

steven@oogkliniekbrugge.be

29/1/2026

Oogarts gezocht voor privépraktijk nabij Gent

Voor een goed uitgebouwde privé-oogartsenpraktijk in de regio Gent zijn wij op zoek naar een gemotiveerde oogarts (m/v/x) om ons team te versterken. De praktijk beschikt over een moderne infrastructuur en een aangename werkomgeving, met ondersteuning van een ervaren medisch secretaresse die naast administratieve taken ook vooronderzoeken uitvoert.

Uitrusting van de praktijk:

- Gezichtsveldonderzoek
- OCT
- Biometrie
- YAG-laser
- Lokaal voor kleine ingrepen

Wij bieden:

- Flexibele samenwerkingsvorm (voltijds/deeltijds bespreekbaar)
- Goed georganiseerde praktijk met efficiënte ondersteuning
- Moderne apparatuur en comfortabel ingerichte consultatieruimtes
- Mogelijkheid tot inkoop/participatie in de praktijk

.../.. >

KLEINE AANKONDIGINGEN / PETITES ANNONCES

Profiel:

- Erkend oogarts (of laatste jaar opleiding)
- Teamgericht, patiëntvriendelijk en kwaliteitsbewust

Interesse om te werken in een dynamische privépraktijk met groeiperspectief in een aantrekkelijke regio?

Neem dan vrijblijvend contact op voor meer informatie of een verkennend gesprek.

Tel: 0032478723626

margotclaus@hotmail.com

26/1/2026

Orthoptiste polyvalent(e) – Temps plein (H/F)

Cabinet d'ophtalmologie situé au nord de Bruxelles,

Diplôme d'orthoptiste reconnu

- Expérience en cabinet d'ophtalmologie souhaitée
- Excellente polyvalence entre activités cliniques et administratives
- Bonne maîtrise du néerlandais et de l'anglais (le français étant indispensable)
- À l'aise avec les outils informatiques et logiciels médicaux
- Sens de l'organisation, autonomie et rigueur

Tel: 02/4269904

info@drmathys.be

19/1/2026

Vacature oogarts praktijk Rotselaar

Vanaf zomer 2026: Onze oogartspraktijk te Rotselaar verwelkomt graag een nieuwe collega oogarts.

- full time praktijkassistente aanwezig voor telefonie, onthaal en technische onderzoeken (behalve op woensdag namiddag)
 - dossier software: Eyefile
 - gemeenschappelijk te gebruiken apparatuur:
 - ARK, NCT, focometer
 - Haag Streit Octopus 900 perimeter met EyeSuite software
 - Nidek biometer
 - Ellex UltraQ Yag laser
 - Topcon Maestro2 OCT
 - Retinomax
 - icare ic200 tonometer
 - Goldmann perimeter
 - eigen kabinet uitgerust met Haag-Streit BQ900 spleetlamp (led), NIDEK automatische refractor (phoropter)
- Aarzel niet om een kijkje te komen nemen.

Contactgegevens:

Karolien Maris- Dorpsplein 13/A - 3110 Rotselaar

Tel: 0476435513

maris@oogartsrotselaar.com